ABIVAX Société Anonyme (0RA9.L)
EUR 5.15
(-2.65%)
EUR 5.15
(-2.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -147.74 Million EUR | -111.52% |
| 2022 | -69.84 Million EUR | -68.89% |
| 2021 | -41.35 Million EUR | -10.14% |
| 2020 | -37.55 Million EUR | -22.58% |
| 2019 | -30.63 Million EUR | -93.6% |
| 2018 | -15.82 Million EUR | -41.0% |
| 2017 | -11.22 Million EUR | 21.57% |
| 2016 | -14.3 Million EUR | 10.32% |
| 2015 | -15.95 Million EUR | -96.99% |
| 2014 | -8.09 Million EUR | -37.43% |
| 2013 | -5.89 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -81.63 Million EUR | 0.0% |
| 2023 Q2 | -51.95 Million EUR | 0.0% |
| 2023 Q4 | -95.78 Million EUR | 0.0% |
| 2023 FY | -147.74 Million EUR | -111.52% |
| 2022 Q4 | -40.29 Million EUR | 0.0% |
| 2022 FY | -69.84 Million EUR | -68.89% |
| 2022 Q2 | -29.55 Million EUR | 0.0% |
| 2021 FY | -41.35 Million EUR | -10.14% |
| 2021 Q4 | -24.82 Million EUR | 0.0% |
| 2021 Q2 | -16.53 Million EUR | 0.0% |
| 2020 Q4 | -22.12 Million EUR | 0.0% |
| 2020 Q2 | -15.42 Million EUR | 0.0% |
| 2020 FY | -37.55 Million EUR | -22.58% |
| 2019 Q2 | -14.17 Million EUR | 0.0% |
| 2019 FY | -30.63 Million EUR | -93.6% |
| 2019 Q4 | -16.46 Million EUR | 0.0% |
| 2018 Q4 | -8.57 Million EUR | 0.0% |
| 2018 FY | -15.82 Million EUR | -41.0% |
| 2018 Q2 | -7.24 Million EUR | 0.0% |
| 2017 Q2 | -5.54 Million EUR | 0.0% |
| 2017 FY | -11.22 Million EUR | 21.57% |
| 2017 Q4 | -5.67 Million EUR | 0.0% |
| 2016 Q4 | -6.03 Million EUR | 0.0% |
| 2016 Q2 | -8.27 Million EUR | 0.0% |
| 2016 FY | -14.3 Million EUR | 10.32% |
| 2015 FY | -15.95 Million EUR | -96.99% |
| 2015 Q4 | -8.78 Million EUR | 0.0% |
| 2015 Q2 | -7.17 Million EUR | 0.0% |
| 2014 Q4 | -4.42 Million EUR | -199900.0% |
| 2014 Q2 | -653 Thousand EUR | -199900.0% |
| 2014 Q1 | -326.50 EUR | 0.0% |
| 2014 FY | -8.09 Million EUR | -37.43% |
| 2014 Q3 | -2213.50 EUR | 99.66% |
| 2013 FY | -5.89 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Boiron SA | 35.82 Million EUR | 512.371% |
| Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 186.735% |
| Vetoquinol SA | 55.56 Million EUR | 365.911% |
| Valneva SE | -101.42 Million EUR | -45.659% |
| AB Science S.A. | -10.04 Million EUR | -1370.342% |
| Nanobiotix S.A. | -39.7 Million EUR | -272.141% |
| PHAXIAM Therapeutics S.A. | -23.48 Million EUR | -529.002% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -421.276% |
| BioSenic S.A. | -28.77 Million EUR | -413.378% |
| Formycon AG | 75.79 Million EUR | 294.921% |